Use of the digital flicker test in patients with neuritis nervi optici and differential-diagnostically important diseases and investigation of the pathophysiology of the darkness enhancement phenomenon

Use of the digital flicker test in patients with neuritis nervi optici and differential-diagnostically important diseases and investigation of the pathophysiology of the darkness enhancement phenomenon - DFTinNNOandDiffDiag

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031081

Enrollment

Registered

2023-01-24

Start date

2022-06-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H46 H47 C71 H30 H35

Interventions

Group 1: Part 1: Use of the digital flicker test (DFT) in patients with demyelinating and differentially important diseases to determine the specificity of the test. Patients with atypical NNO and tho

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Unilateral acute or subacute visual loss with or without optic disc changes.

Exclusion criteria

Exclusion criteria: Epilepsy, visual field defects of other etiology, visual acuity < 0.05 decimal.

Design outcomes

Primary

Measure	Time frame
Determination of the Specificity and Sensitivity of the Digital Flicker Test (DFT)	—

Secondary

Measure	Time frame
Investigation of the darkness enhancement phenomenon by selective stimulation of retinal ON- and OFF- center neurons in patients with neuritis nervi optici and ocularly healthy subjects	—

Countries

Germany

Contacts

Public ContactSusanne Trauzettel-Klosinski

Forschungseinheit für Visuelle Rehabilitation, Department für Augenheilkunde, Universitätsklinikum Tübingen

susanne.trauzettel-klosinski@uni-tuebingen.de+4970712980818

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026